HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death. "I don't think I need to convince anyone here that we need to discover new ...
Combination therapy is a common cancer treatment strategy, the rationale being that two drugs together may be more effective than either one alone. Seagen and Nurix Therapeutics are embracing the ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
Antibody-drug conjugates (ADCs) represent a groundbreaking approach to cancer treatment. They involve combining monoclonal antibodies with chemotherapy drugs, enabling the precise targeting of cancer ...
Raising $94 million in a series A round, South San Francisco-based Firefly Bio Inc. has emerged from stealth to advance its Firelink linker platform technology to develop degrader-antibody conjugates ...
13d
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a ...
The pharmaceutical industry’s antibody-drug conjugate( ADC) deal spree continues. AbbVie says it will buy ImmunoGen for about $10 billion, adding to a series of multi-billion dollar acquisitions built ...
News-Medical.Net on MSN
Precision immunotherapy for TRBC2-positive T-cell malignancies
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
Researchers from Elpiscience Biopharmaceuticals Inc. discussed the discovery and preclinical characterization of a novel NKG2A antibody-IL-2 mutant fusion protein – ES-015.129 – being developed as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback